Chardan Capital Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Key Points

• Krystal Biotech's stock has been given a "buy" rating by Chardan Capital, with a price target of $219.00, indicating a potential upside of 62.29% from its previous close.
• The company's latest earnings report showed an EPS of $1.29, outperforming analyst expectations of $1.08, alongside a revenue of $96.04 million.
• Institutional investors hold 86.29% of Krystal Biotech's stock, with notable recent increases in positions from firms like LPL Financial and JPMorgan Chase.

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $219.00 target price on the stock. Chardan Capital's price objective would indicate a potential upside of 57.94% from the stock's previous close.

A number of other research firms have also issued reports on KRYS. Citigroup restated a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Bank of America cut their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $210.22.

Krystal Biotech Stock Performance

Shares of KRYS traded up $2.56 during mid-day trading on Tuesday, reaching $138.66. 332,066 shares of the company's stock traded hands, compared to its average volume of 422,365. The business's 50-day moving average price is $141.94 and its 200-day moving average price is $155.36. The stock has a market capitalization of $4.01 billion, a P/E ratio of 28.18 and a beta of 0.70. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. Equities research analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the transaction, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 49,800 shares of company stock valued at $7,487,943. Company insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently modified their holdings of the stock. Brooklyn Investment Group increased its stake in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after acquiring an additional 179 shares in the last quarter. Twin Tree Management LP bought a new stake in shares of Krystal Biotech during the first quarter worth $29,000. Fifth Third Bancorp raised its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the period. Finally, First Horizon Advisors Inc. lifted its position in Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).